PRNP (Major prion protein) variants and mutations
PRNP (also known as Major prion protein) is a human protein-coding gene encoding a major prion protein. Its normal cellular form is enriched in the nervous system, but misfolding into self-propagating conformations can template further protein conversion. This process causes prion diseases, while germline pathogenic variants underlie inherited Creutzfeldt-Jakob disease, Gerstmann-Straussler-Scheinker disease, and fatal familial insomnia. This analysis covers 617 PRNP variants and mutations. Of these, 80% have computational variant effect predictions. Disease context includes Gerstmann-Straussler-Scheinker syndrome, Creutzfeldt Jacob disease, and Huntington disease-like 1. Example PRNP variants include M1?, A2E, and A2V.
Variant analysis overview
- Gene: PRNP
- Protein: Major prion protein
- UniProt accession: P04156
- Organism: Homo sapiens
- Variants analyzed: 617
- Variant scope: all variants
- Completed: 2026-08-18
Variant and mutation evidence
- Variant composition: 350 unspecified-consequence records; 119 synonymous variants; 104 missense variants; 11 stop-gained variants; 15 frameshift variants; 1 in-frame insertions; 11 in-frame deletions; 1 stop retained variant; 5 substitution
- Prediction scores: 491 variants have prediction scores (80% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: Gerstmann-Straussler-Scheinker syndrome, Creutzfeldt Jacob disease, Huntington disease-like 1, fatal familial insomnia, inherited Creutzfeldt-Jakob disease, dementia, neurodegenerative disease, hereditary disease, prion disease, cerebral amyloid angiopathy, inherited prion disease, sporadic Creutzfeld Jacob disease.
Protein structure and variant hotspots
- Protein features: 12 binding sites; 2 post-translational modification sites.
- PTM context: 4 variants overlap post-translational modification sites.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, 3D Hotspot Analysis, Interaction Network Analysis, Protein Data Bank, AlphaFold DB, gnomAD constraint, Open Targets, MaveDB, LitVar.
Notable PRNP variants
Examples include M1?, A2E, A2V, A2A, N3K, N3N, L4F, L4H. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- M1?, NCI-TCGA Cosmic COSV6517, cosmic curated COSV65174, Variant assessed as somatic; high impact.
- A2E (p.Ala2Glu), cosmic curated COSV65174, REVEL 0.18, CADD 14.60
- A2V (p.Ala2Val), rs748227837, ClinGen CA9751991, cosmic curated COSV10823, NCI-TCGA Cosmic COSV6517, REVEL 0.16, CADD 7.63, Conflicting interpretations, Inherited prion disease; Huntington disease-like 1
- A2A (p.Ala2Ala), rs1405257982, gnomAD 20-4699226-G-A, CADD 1.21
- N3K (p.Asn3Lys), TOPMed rs1922369989, REVEL 0.08, CADD 1.01
- N3N (p.Asn3Asn), gnomAD 20-4699229-C-T, CADD 1.92
- L4F (p.Leu4Phe), cosmic curated COSV10823
- L4H (p.Leu4His), ExAC rs772131924, gnomAD rs772131924, REVEL 0.36, CADD 22.70
- L4R (p.Leu4Arg), ExAC rs772131924, gnomAD rs772131924, REVEL 0.35, CADD 22.70
- G5A (p.Gly5Ala), NCI-TCGA Cosmic COSV6517, cosmic curated COSV65173, Variant assessed as somatic; moderate impact.
- G5D (p.Gly5Asp), Ensembl rs1031763509
- G5G (p.Gly5Gly), gnomAD 20-4699235-C-A, CADD 8.81
- C6F (p.Cys6Phe), Ensembl rs2122226560
- C6G (p.Cys6Gly), gnomAD 20-4699236-T-G, REVEL 0.23, CADD 16.40
- W7* (p.Trp7Ter), gnomAD 20-4699241-G-A, CADD 37.00
- M8V (p.Met8Val), ExAC rs760925175, gnomAD rs760925175, REVEL 0.28, CADD 10.30
- L11I (p.Leu11Ile), cosmic curated COSV10105
- F12S (p.Phe12Ser), ExAC rs771239157, TOPMed rs771239157, gnomAD rs771239157, REVEL 0.67, CADD 28.50
- F12C (p.Phe12Cys), gnomAD 20-4699253-CTT-C, CADD 27.90
- F12L (p.Phe12Leu), gnomAD 20-4699254-T-C, REVEL 0.54, CADD 23.60
- V13M (p.Val13Met), TOPMed rs1922371701
- A14S (p.Ala14Ser), gnomAD rs926468769, REVEL 0.30, CADD 22.90, Uncertain significance, Inborn genetic diseases
- A14T (p.Ala14Thr), gnomAD rs926468769, REVEL 0.24, CADD 21.90, Uncertain significance
- A14V (p.Ala14Val), Ensembl rs1922372468
- A14A (p.Ala14Ala), rs1922372775, gnomAD 20-4699262-C-T, CADD 10.80
- T15I (p.Thr15Ile), cosmic curated COSV65173, REVEL 0.39, CADD 19.40
- T15K (p.Thr15Lys), TOPMed rs1310503089
- T15P (p.Thr15Pro), TOPMed rs1355410515
- T15A (p.Thr15Ala), gnomAD 20-4699263-A-G, REVEL 0.25, CADD 15.10
- T15T (p.Thr15Thr), gnomAD 20-4699265-A-G, CADD 5.72
- W16L (p.Trp16Leu), TOPMed rs1922373718
- W16S (p.Trp16Ser), NCI-TCGA Cosmic COSV1010, cosmic curated COSV10105, Variant assessed as somatic; moderate impact.
- W16* (p.Trp16Ter), gnomAD 20-4699268-G-A, CADD 36.00
- S17T (p.Ser17Thr), rs368154579, ClinGen CA9751996, ClinVar RCV001091285, ClinVar RCV003626668, REVEL 0.24, CADD 16.90, Uncertain significance, Huntington disease-like 1; not provided
- S17R (p.Ser17Arg), gnomAD 20-4699271-T-A, REVEL 0.63, CADD 23.80
- D18E (p.Asp18Glu), 1000Genomes rs548116564, ExAC rs548116564, TOPMed rs548116564, gnomAD rs548116564, REVEL 0.17, CADD 9.39, Likely benign
- D18N (p.Asp18Asn), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- D18D (p.Asp18Asp), rs548116564, gnomAD 20-4699274-C-T, CADD 6.24
- L19V (p.Leu19Val), TOPMed rs1261971734, gnomAD rs1261971734, REVEL 0.24, CADD 0.01
- L19L (p.Leu19Leu), rs1261971734, gnomAD 20-4699275-C-T, CADD 0.70
- G20G (p.Gly20Gly), rs112885437, gnomAD 20-4699280-C-T, CADD 9.02
- L21I (p.Leu21Ile), ExAC rs776137568, gnomAD rs776137568, REVEL 0.44, CADD 23.00
- L21L (p.Leu21Leu), gnomAD 20-4699283-C-T, CADD 8.37
- C22C (p.Cys22Cys), rs762612626, gnomAD 20-4699286-C-T, CADD 9.14
- K23Q (p.Lys23Gln), gnomAD 20-4699287-A-C, REVEL 0.64, CADD 25.30
- K23M (p.Lys23Met), gnomAD 20-4699288-A-T, REVEL 0.71, CADD 26.40
- K23K (p.Lys23Lys), rs763637586, gnomAD 20-4699289-G-A, CADD 9.31
- K24R (p.Lys24Arg), Ensembl rs1197612803, REVEL 0.55, CADD 25.80
- K24K (p.Lys24Lys), rs1922376980, gnomAD 20-4699292-G-A, CADD 9.43
- R25C (p.Arg25Cys), rs751211144, ExAC rs751211144, TOPMed rs751211144, gnomAD rs751211144, REVEL 0.64, CADD 26.10, Variant assessed as somatic; moderate impact.
- R25H (p.Arg25His), rs146939732, ClinGen CA311093172, ClinVar RCV002922918, ESP rs146939732, REVEL 0.51, CADD 26.30, Uncertain significance, Huntington disease-like 1
- R25L (p.Arg25Leu), gnomAD 20-4699294-G-T, REVEL 0.57, CADD 25.90
- P26A (p.Pro26Ala), rs11538755, ClinGen CA408151575, ClinVar RCV001143501, Ensembl rs11538755, AlphaMissense 0.23, MetaLR 0.88, Uncertain significance, Inherited prion disease
- P26L (p.Pro26Leu), NCI-TCGA Cosmic COSV6517, cosmic curated COSV65173, REVEL 0.47, CADD 24.80, Uncertain significance, not provided
- P26R (p.Pro26Arg), TOPMed rs1922378268, gnomAD rs1922378268, REVEL 0.48, CADD 24.40
- P26T (p.Pro26Thr), Ensembl rs11538755, Uncertain significance
- P26P (p.Pro26Pro), rs756969320, gnomAD 20-4699298-G-A, CADD 4.56
- K27K (p.Lys27Lys), rs1156934207, gnomAD 20-4699301-G-A, CADD 7.74
- P28H (p.Pro28His), Ensembl rs11538762
- P28S (p.Pro28Ser), TOPMed rs1369247240, gnomAD rs1369247240, REVEL 0.49, CADD 22.90
- P28T (p.Pro28Thr), TOPMed rs1369247240, gnomAD rs1369247240, REVEL 0.51, CADD 23.90
- P28A (p.Pro28Ala), gnomAD 20-4699302-C-G, REVEL 0.49, CADD 22.60
- P28L (p.Pro28Leu), gnomAD 20-4699303-C-T, REVEL 0.62, CADD 24.90
- G29E (p.Gly29Glu), rs989264799, ClinGen CA311093181, ClinVar RCV001991499, TOPMed rs989264799, AlphaMissense 0.89, MetaLR 0.91, Uncertain significance, Huntington disease-like 1
- G30E (p.Gly30Glu), NCI-TCGA Cosmic COSV6517, cosmic curated COSV65173, Variant assessed as somatic; moderate impact.
- G30R (p.Gly30Arg), rs2514371918, ClinVar RCV004592464, Uncertain significance, not provided
- W31R (p.Trp31Arg), gnomAD rs1360068809, REVEL 0.48, CADD 23.50
- W31* (p.Trp31Ter), gnomAD 20-4699312-G-A, CADD 38.00
- N32I (p.Asn32Ile), Ensembl rs1922380574
- T33P (p.Thr33Pro), ExAC rs767032162, REVEL 0.51, CADD 24.70
- T33S (p.Thr33Ser), ExAC rs767032162
- T33I (p.Thr33Ile), gnomAD 20-4699318-C-T, REVEL 0.43, CADD 21.40
- T33T (p.Thr33Thr), gnomAD 20-4699319-T-C, CADD 5.48
- G34A (p.Gly34Ala), ExAC rs780030584, gnomAD rs780030584, REVEL 0.55, CADD 24.80
- G34R (p.Gly34Arg), NCI-TCGA Cosmic COSV1010, cosmic curated COSV10105, REVEL 0.54, CADD 24.50, Variant assessed as somatic; moderate impact.
- G34V (p.Gly34Val), ExAC rs780030584, gnomAD rs780030584, REVEL 0.69, CADD 23.50
- G34G (p.Gly34Gly), rs1255322020, gnomAD 20-4699322-G-A, CADD 7.39
- G35A (p.Gly35Ala), NCI-TCGA Cosmic COSV1010, ExAC rs758452370, gnomAD rs758452370, REVEL 0.59, CADD 24.90, Variant assessed as somatic; high impact.
- G35D (p.Gly35Asp), cosmic curated COSV65173, REVEL 0.61, CADD 25.30
- G35S (p.Gly35Ser), cosmic curated COSV10592, ExAC rs749207734, gnomAD rs749207734, REVEL 0.50, CADD 23.30
- G35G (p.Gly35Gly), gnomAD 20-4699325-C-T, CADD 4.10
- R37* (p.Arg37Ter), ExAC rs11538763, gnomAD rs11538763, CADD 36.00
- R37G (p.Arg37Gly), ExAC rs11538763, gnomAD rs11538763, REVEL 0.65, CADD 25.60
- R37Q (p.Arg37Gln), cosmic curated COSV65173, gnomAD rs1313855686, REVEL 0.65, CADD 28.20, Uncertain significance, Inborn genetic diseases
- R37P (p.Arg37Pro), gnomAD 20-4699330-G-C, REVEL 0.69, CADD 28.40
- Y38N (p.Tyr38Asn), gnomAD 20-4699332-T-A, REVEL 0.59, CADD 23.70
- Y38Y (p.Tyr38Tyr), gnomAD 20-4699334-C-T, CADD 7.09
- P39L (p.Pro39Leu), ExAC rs747019990, TOPMed rs747019990, gnomAD rs747019990, REVEL 0.88, CADD 23.40, Conflicting interpretations, Inherited prion disease; Huntington disease-like 1
- P39S (p.Pro39Ser), ESP rs11538756, TOPMed rs11538756, gnomAD rs11538756, REVEL 0.70, CADD 23.40
- P39T (p.Pro39Thr), ESP rs11538756, TOPMed rs11538756, gnomAD rs11538756
- P39A (p.Pro39Ala), gnomAD 20-4699335-C-G, REVEL 0.73, CADD 24.00
- P39Q (p.Pro39Gln), gnomAD 20-4699336-C-A, REVEL 0.72, CADD 25.10
- P39P (p.Pro39Pro), rs771206868, gnomAD 20-4699337-G-A, CADD 1.61
- p.Gly40 Gln41insArgGlySerArgTyrP, rs761410800, gnomAD 20-4699320-G-GGGG, CADD 18.40
- G40G (p.Gly40Gly), rs202102378, gnomAD 20-4699340-G-A, CADD 5.60
- Q41* (p.Gln41Ter), gnomAD rs1224211901, CADD 36.00
- Q41H (p.Gln41His), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- G42D (p.Gly42Asp), cosmic curated COSV10105, ExAC rs746303257, TOPMed rs746303257, gnomAD rs746303257, REVEL 0.52, CADD 25.10
- G42S (p.Gly42Ser), gnomAD rs1287360365, REVEL 0.19, CADD 21.20
- G42G (p.Gly42Gly), gnomAD 20-4699346-C-A, CADD 7.37
- S43N (p.Ser43Asn), gnomAD rs1198634509, REVEL 0.26, CADD 16.40
- P44L (p.Pro44Leu), Ensembl rs1922387125
- P44S (p.Pro44Ser), TOPMed rs943366320, gnomAD rs943366320, REVEL 0.42, CADD 22.60
- P44T (p.Pro44Thr), cosmic curated COSV65173
- G46S (p.Gly46Ser), cosmic curated COSV10890, Ensembl rs1922387474, REVEL 0.52, CADD 23.70
- G46G (p.Gly46Gly), gnomAD 20-4699358-C-T, CADD 11.90
- N47D (p.Asn47Asp), ExAC rs770271370, gnomAD rs770271370, REVEL 0.50, CADD 23.40, Uncertain significance, Huntington disease-like 1
- N47N (p.Asn47Asn), gnomAD 20-4699361-C-T, CADD 10.30
- R48C (p.Arg48Cys), TOPMed rs11538764, REVEL 0.56, CADD 27.10
- R48H (p.Arg48His), cosmic curated COSV10582, TOPMed rs945136467, gnomAD rs945136467, REVEL 0.47, CADD 24.80, Conflicting interpretations, not provided; Inherited prion disease; Huntington disease-like 1
- R48S (p.Arg48Ser), TOPMed rs11538764
- Y49C (p.Tyr49Cys), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- Y49H (p.Tyr49His), gnomAD 20-4699365-T-C, REVEL 0.62, CADD 24.20
- Y49* (p.Tyr49Ter), gnomAD 20-4699367-C-G, CADD 34.00
- Y49Y (p.Tyr49Tyr), gnomAD 20-4699367-C-T, CADD 7.00
- P50L (p.Pro50Leu), TOPMed rs1379757697, gnomAD rs1379757697
- P50R (p.Pro50Arg), TOPMed rs1379757697, gnomAD rs1379757697, REVEL 0.66, CADD 23.80
- P51S (p.Pro51Ser), TOPMed rs760774153, gnomAD rs760774153, REVEL 0.36, CADD 19.40
- Q52* (p.Gln52Ter), cosmic curated COSV10531
- Q52P (p.Gln52Pro), gnomAD rs1425430077, REVEL 0.50, CADD 23.70
- G53V (p.Gly53Val), gnomAD rs1165685871
- G53G (p.Gly53Gly), rs776188950, gnomAD 20-4699379-C-T, CADD 1.02
- G54S (p.Gly54Ser), rs763524380, ClinGen CA9752018, ClinVar RCV000326386, ClinVar RCV000527040, REVEL 0.58, CADD 22.30, Benign/Likely benign, not provided; Inherited prion disease; Huntington disease-like 1
- G54V (p.Gly54Val), TOPMed rs1922394234
- G54G (p.Gly54Gly), rs770846581, gnomAD 20-4699382-T-C, CADD 5.79
- G56G (p.Gly56Gly), rs1299262651, gnomAD 20-4699388-C-G, CADD 10.20
- W57* (p.Trp57Ter), TOPMed rs1922395206
- G58W (p.Gly58Trp), ExAC rs773938628, TOPMed rs773938628, gnomAD rs773938628, REVEL 0.68, CADD 27.40
- G58R (p.Gly58Arg), gnomAD 20-4699392-G-A, REVEL 0.72, CADD 26.40
- G58G (p.Gly58Gly), rs1380117291, gnomAD 20-4699394-G-T, CADD 0.84
- Q59K (p.Gln59Lys), Ensembl rs1922396359
- Q59S (p.Gln59Ser), NCI-TCGA TCGA novel, Variant assessed as somatic; high impact.
- Q59R (p.Gln59Arg), gnomAD 20-4699395-CA-C, CADD 27.90
- P60L (p.Pro60Leu), ExAC rs761172095, gnomAD rs761172095, REVEL 0.68, CADD 23.30
- P60T (p.Pro60Thr), gnomAD 20-4699398-C-A, REVEL 0.65, CADD 24.30
- P60P (p.Pro60Pro), rs1386720703, gnomAD 20-4699400-T-C, CADD 10.20
- H61L (p.His61Leu), Ensembl rs1555781937
- H61Y (p.His61Tyr), NCI-TCGA Cosmic COSV1010, cosmic curated COSV10105, Variant assessed as somatic; moderate impact.
- p.His61 Gly62delinsArg, gnomAD 20-4699401-CATG-C, CADD 18.60
- H61R (p.His61Arg), gnomAD 20-4699402-A-G, REVEL 0.62, CADD 23.30
- G62D (p.Gly62Asp), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- G62S (p.Gly62Ser), TOPMed rs1922397920, REVEL 0.52, CADD 20.60
- G62V (p.Gly62Val), gnomAD 20-4699405-G-T, REVEL 0.56, CADD 22.50
- G63S (p.Gly63Ser), TOPMed rs1159538855, REVEL 0.60, CADD 22.80
- G63V (p.Gly63Val), gnomAD 20-4699408-G-T, REVEL 0.64, CADD 23.90
- G63G (p.Gly63Gly), rs767207185, gnomAD 20-4699409-T-A, CADD 1.14
- G64S (p.Gly64Ser), cosmic curated COSV10531, Uncertain significance, not provided
- W65* (p.Trp65Ter), Ensembl rs1922399219
- W65G (p.Trp65Gly), TOPMed rs1382858633, gnomAD rs1382858633, REVEL 0.73, CADD 23.60
- G66G (p.Gly66Gly), rs750069679, gnomAD 20-4699418-G-A, CADD 0.43
- Q67K (p.Gln67Lys), TOPMed rs1415471911, REVEL 0.54, CADD 21.70
- P68L (p.Pro68Leu), Ensembl rs1568534249, REVEL 0.75, CADD 23.70
- p.Pro68 Gln91del, gnomAD 20-4699394-GCAGCC, CADD 18.60
- P68P (p.Pro68Pro), rs532493114, gnomAD 20-4699424-T-C, CADD 1.13
- H69Q (p.His69Gln), Ensembl rs1922403676
- H69R (p.His69Arg), gnomAD rs1247563362
- H69Y (p.His69Tyr), Ensembl rs1922402078, REVEL 0.53, CADD 18.80
- H69M (p.His69Met), rs1282604670, gnomAD 20-4699423-CT-C, CADD 5.42
- H69P (p.His69Pro), rs1568534300, gnomAD 20-4699425-CATGGT, CADD 29.40
- p.His69 Gly70delinsArg, rs755064098, gnomAD 20-4699425-CATG-C, CADD 14.10
- G70S (p.Gly70Ser), TOPMed rs1922404016
- G71D (p.Gly71Asp), gnomAD rs1355212975, REVEL 0.60, CADD 22.10
- G71S (p.Gly71Ser), ExAC rs755959420, gnomAD rs755959420, REVEL 0.53, CADD 22.20
- G71G (p.Gly71Gly), gnomAD 20-4699433-T-A, CADD 0.26
- G72C (p.Gly72Cys), TOPMed rs1209553535, gnomAD rs1209553535, Uncertain significance
- G72R (p.Gly72Arg), rs1209553535, ClinGen CA408151863, ClinVar RCV002915098, TOPMed rs1209553535, REVEL 0.56, CADD 22.60, Uncertain significance, Inborn genetic diseases
- G72S (p.Gly72Ser), TOPMed rs1209553535, gnomAD rs1209553535, REVEL 0.24, CADD 14.00, Uncertain significance
- W73C (p.Trp73Cys), TOPMed rs929341781, gnomAD rs929341781, REVEL 0.75, CADD 23.80
- W73S (p.Trp73Ser), Ensembl rs1922405887, Uncertain significance, not provided
- W73G (p.Trp73Gly), gnomAD 20-4699437-T-G, REVEL 0.80, CADD 23.40
- W73* (p.Trp73Ter), gnomAD 20-4699438-G-A, CADD 36.00
- G74W (p.Gly74Trp), gnomAD rs1459419755
- G74G (p.Gly74Gly), rs766136217, gnomAD 20-4699442-G-T, CADD 0.04
- Q75* (p.Gln75Ter), ExAC rs753810713, TOPMed rs753810713, gnomAD rs753810713, CADD 35.00
- Q75E (p.Gln75Glu), ExAC rs753810713, TOPMed rs753810713, gnomAD rs753810713, REVEL 0.50, CADD 19.60
- Q75S (p.Gln75Ser), NCI-TCGA TCGA novel, Variant assessed as somatic; high impact.
- Q75del (p.Gln75del), rs1197265879, gnomAD 20-4699441-GGCA-G, CADD 12.80
- Q75K (p.Gln75Lys), gnomAD 20-4699443-C-A, REVEL 0.64, CADD 20.40
- Q75R (p.Gln75Arg), gnomAD 20-4699444-A-G, REVEL 0.69, CADD 22.10
- Q75Q (p.Gln75Gln), rs776922173, gnomAD 20-4699445-G-A, CADD 1.66
Public PRNP analysis runs
- PRNP analysis run — PRNP (617 variants) — completed 2026-08-18